Morgan Stanley
PMVP icon

Morgan Stanley’s PMV Pharmaceuticals PMVP Stock Holding History

Morgan Stanley’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
864,311
+765,436
+774% +$973K ﹤0.01% 5109
2025
Q4 		$124K Buy
98,875
+66,480
+205% +$89K ﹤0.01% 6113
2025
Q3 		$45.4K Sell
32,395
-1,700
-5% -$2.35K ﹤0.01% 6440
2025
Q2 		$36.1K Buy
34,095
+6,029
+21% +$5.91K ﹤0.01% 6468
2025
Q1 		$30.6K Sell
28,066
-13,697
-33% -$18.6K ﹤0.01% 6432
2024
Q4 		$63.1K Sell
41,763
-17,658
-30% -$28K ﹤0.01% 6218
2024
Q3 		$88.5K Sell
59,421
-59,816
-50% -$92.4K ﹤0.01% 6049
2024
Q2 		$193K Sell
119,237
-302,591
-72% -$546K ﹤0.01% 5696
2024
Q1 		$717K Sell
421,828
-376,528
-47% -$703K ﹤0.01% 5140
2023
Q4 		$2.47M Buy
798,356
+563,037
+239% +$1.49M ﹤0.01% 4807
2023
Q3 		$1.44M Sell
235,319
-120,627
-34% -$829K ﹤0.01% 4587
2023
Q2 		$2.23M Sell
355,946
-274,313
-44% -$1.44M ﹤0.01% 4362
2023
Q1 		$3.01M Sell
630,259
-509,003
-45% -$3.58M ﹤0.01% 4188
2022
Q4 		$9.91M Sell
1,139,262
-174,641
-13% -$1.86M ﹤0.01% 3102
2022
Q3 		$15.6M Sell
1,313,903
-1,772,060
-57% -$25.6M ﹤0.01% 2469
2022
Q2 		$44M Sell
3,085,963
-1,303,107
-30% -$19M 0.01% 1476
2022
Q1 		$91.4M Buy
4,389,070
+4,063,103
+1,246% +$71.7M 0.01% 919
2021
Q4 		$7.53M Buy
325,967
+288,078
+760% +$6.96M ﹤0.01% 3277
2021
Q3 		$1.13M Sell
37,889
-30,439
-45% -$972K ﹤0.01% 4975
2021
Q2 		$2.33M Buy
68,328
+58,105
+568% +$1.94M ﹤0.01% 4513
2021
Q1 		$337K Sell
10,223
-21,573
-68% -$850K ﹤0.01% 5369
2020
Q4 		$1.96M Buy
31,796
+24,896
+361% +$977K ﹤0.01% 4175
2020
Q3 		$245K Buy
+6,900
New +$254K ﹤0.01% 5004

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley's PMVP Position: Q1 2026 in Review

Morgan Stanley increased its PMV Pharmaceuticals (PMVP) stake by 774% in Q1 2026, buying an estimated $973K and bringing the position to 864,311 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5109.

Morgan Stanley first reported a position in PMVP in Q3 2020 and has held it in 23 quarters since. The position peaked at $91.4M in Q1 2022. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Morgan Stanley held 864,311 shares of PMV Pharmaceuticals worth $1.07M as of Q1 2026.
  • Morgan Stanley bought 765,436 PMV Pharmaceuticals shares in Q1 2026, an estimated $973K.
  • PMV Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5109 holding.
  • Morgan Stanley first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's PMV Pharmaceuticals position peaked at $91.4M in Q1 2022.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.